| Literature DB >> 27023756 |
Luciano Selistre1,2,3,4,5, Muriel Rabilloud5,6,7, Pierre Cochat6,7,8,9, Vandréa de Souza1,2,4, Jean Iwaz5,6,7, Sandrine Lemoine1,8,10, Françoise Beyerle1,11, Carlos E Poli-de-Figueiredo3, Laurence Dubourg1,6,8.
Abstract
BACKGROUND: Estimating kidney glomerular filtration rate (GFR) is of utmost importance in many clinical conditions. However, very few studies have evaluated the performance of GFR estimating equations over all ages and degrees of kidney impairment. We evaluated the reliability of two major equations for GFR estimation, the CKD-EPI and Schwartz equations, with urinary clearance of inulin as gold standard. METHODS ANDEntities:
Mesh:
Substances:
Year: 2016 PMID: 27023756 PMCID: PMC4811544 DOI: 10.1371/journal.pmed.1001979
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Formulas used for the estimation of glomerular filtration rate (ml/min/1.73 m2).
| Equation | Condition | Formula |
|---|---|---|
|
| Female; PCr ≤ 61.88 μmol/l | eGFR = 144 × [PCr (μmol/l)/61.88]−0.329 × [0.993]Age × [1.159 if black] |
| Female; PCr > 61.88 μmol/l | eGFR = 144 × [PCr (μmol/l)/61.88]−1.209 × [0.993]Age × [1.159 if black] | |
| Male; PCr ≤ 79.56 μmol/l | eGFR = 141 × [PCr (μmol/l)/79.56]−0.411 × [0.993]Age × [1.159 if black] | |
| Male; PCr > 79.56 μmol/l | eGFR = 141 × [PCr (μmol/l)/79.56]−1.209 × [0.993]Age × [1.159 if black] | |
|
| eGFR = 36.5 × height (cm)/PCr (μmol/l) |
To convert PCr values in μmol/l to mg/dl, divide by 88.4.
eGFR, estimated GFR.
Fig 1Flow chart of the study.
Characteristics of the patients in the different mGFR categories.
| Characteristic | Whole Sample | mGFR Category | ||
|---|---|---|---|---|
| <60 ml/min/1.73 m2 | 60–89 ml/min/1.73 m2 | ≥90 ml/min/1.73 m2 | ||
|
| 10,610 (100.0%) | 3,987 (37.6%) | 3,469 (32.7%) | 3,154 (29.7%) |
|
| 53.4 [41.2; 62.7] | 58.3 [47.8; 67.7] | 51.9 [38.3; 60.7] | 42.9 [31.9; 52.2] |
|
| 11.0 [7.4; 14.8] | 13.1 [8.6; 15.2] | 11.4 [8.2; 15.1] | 10.5 [7.1; 14.6] |
|
| ||||
| 2–12 y | 750 (7.0%) | 58 (1.4%) | 151 (4.4%) | 541 (17.1%) |
| 13–17 y | 430 (4.0%) | 61 (1.5%) | 113 (3.2%) | 256 (8.1%) |
| 18–40 y | 2,326 (22.0%) | 523 (13.1%) | 731 (21.1%) | 1,072 (34.0%) |
| 41–64 y | 5,246 (49.5%) | 2,067 (52.0%) | 1,966 (56.7%) | 1,213 (38.5%) |
| ≥65 y | 1,858 (17.5%) | 1,278 (32.0%) | 508 (14.6%) | 72 (2.3%) |
|
| 4,944 (46.6%) | 1,753 (44.0%) | 1,681 (48.4%) | 1,510 (47.8%) |
|
| 1,550 (14.6%) | 958 (24.0%) | 508 (14.6%) | 84 (2.7%) |
|
| 193 (1.8%) | 7 (0.2%) | 67 (1.9%) | 119 (3.8%) |
|
| 68.0 [57.5; 79.50] | 69.0 [59.0; 80.5] | 66.0 [56.0; 78.0] | 67.0 [57.0; 79.0] |
| Females | 60.0 [52.0; 70.0] | 61.0 [53.0; 72.0] | 59.0 [51.0; 68] | 59.0 [52.0; 69.0] |
| Males | 74.0 [65.0; 85.0] | 74.0 [65.0; 85.0] | 74.0 [64.5; 84.0] | 74.0 [65.0; 85.0] |
|
| 166.0 [159.0; 173.0] | 166.0 [158.0; 173.0] | 166.0 [159.0; 173.0] | 167.0 [160.5; 174.0] |
| Females | 160.0 [155.0; 164.5] | 160.0 [155.5; 165.0] | 160.0 [155.5; 165.0] | 161.0 [157.0; 165.5] |
| Males | 172.0 [167.0; 177.0] | 171.0 [166.0; 176.0] | 172.0 [167.0; 177.0] | 173.0 [168.0; 178.0] |
|
| −0.2414 [−0.7457; 0.5601] | −0.3328 [−0.7197; 0.6329] | −0.2883 [−0.7595; 0.5400] | −0.2155 [−0.7456; 0.5396] |
|
| 1.72 [1.55; 1.90] | 1.77 [1.62; 1.93] | 1.74 [1.59; 1.90] | 1.76 [1.61; 1.93] |
|
| 9,430 | 3,868 | 3,205 | 2,357 |
| Median [IQR] | 24.3 [21.3; 27.9] | 25.0 [21.9; 28.7] | 23.9 [21.1; 27.2] | 23.8 [21.0; 27.2] |
| <18.5 kg/m2 | 606 (6.4%) | 228 (5.8%) | 203 (6.3%) | 175 (7.5%) |
| ≥35.0 kg/m2 | 441 (4.7%) | 251 (6.4%) | 106 (3.3%) | 84 (3.6%) |
|
| 87 [66; 118] | 128 [103; 142] | 82 [69; 98] | 62 [51; 73] |
|
| 70 [48; 94] | 42 [31; 52] | 74 [66; 81] | 106 [97; 117] |
|
| 2.21 [0.76; 12.81] | 6.92 [1.69; 42.12] | 1.47 [0.63; 6.16] | 1.19 [0.61; 3.75] |
|
| ||||
| <3 mg/mmol (<30 mg/g) | 5,861 (55.2%) | 1,380 (34.6%) | 2,225 (64.1%) | 2,255 (71.5%) |
| 3–30 mg/mmol (30–300 mg/g) | 2,957 (27.9%) | 1,448 (36.3%) | 856 (24.7%) | 653 (20.7%) |
| >30 mg/mmol (300 mg/g) | 1,793 (16.9%) | 1,159 (29.1%) | 388 (11.2%) | 246 (7.8%) |
Data are given as n (percent) or median [IQR]. Adults are individuals aged ≥18 y; children and adolescents are individuals aged 2–17 y.
*To convert PCr values to mg/dl, divide by 88.4.
**Ratio of urine albumin to urine creatinine.
Estimation of bias (mean eGFR/mGFR ratio) with the CKD-EPI and Schwartz equations according to age class in the whole sample and in different mGFR categories.
| mGFR Category | Age Class | eGFR/mGFR Ratio (95% CI) | |
|---|---|---|---|
| CKD-EPI Equation | Schwartz Equation | ||
|
| All participants | 1.17 (1.16; 1.18) | 1.08 (1.07; 1.10) |
| <18 y | 1.54 (1.51; 1.56) | 1.03 (1.01; 1.04) | |
| 02–12 y | 1.64 (1.61; 1.66) | 1.04 (1.01; 1.06) | |
| 13–17 y | 1.40 (1.35; 1.44) | 1.01 (0.94; 1.08) | |
| All adults | 1.13 (1.12; 1.14) | 1.08 (1.07; 1.10) | |
| 18–40 y | 1.14 (1.12; 1.16) | 0.96 (0.90; 1.01) | |
| 41–64 y | 1.07 (1.03; 1.11) | 1.09 (1.06; 1.14) | |
| ≥65 y | 0.93 (0.89; 0.97) | 1.24 (1.18; 1.30) | |
|
| All participants | 1.26 (1.24; 1.28) | 1.26 (1.24; 1.28) |
| <18 y | 2.52 (2.34; 2.65) | 1.27 (1.15; 1.40) | |
| 02–12 y | 2.51 (2.38; 2.66) | 1.28 (1.16; 1.40) | |
| 13–17 y | 1.69 (1.57; 1.80) | 1.24 (0.96; 1.53) | |
| All adults | 1.29 (1.25; 1.33) | 1.13 (1.09; 1.17) | |
| 18–40 y | 1.45 (1.27; 1.62) | 1.13 (0.87; 1.38) | |
| 41–64 y | 1.27 (1.11; 1.45) | 1.25 (1.00; 1.50) | |
| ≥65 y | 1.14 (0.97; 1.31) | 1.34 (1.10; 1.59) | |
|
| All participants | 1.15 (1.13; 1.16) | 1.02 (1.01; 1.03) |
| <18 y | 1.76 (1.73; 1.79) | 1.10 (1.06; 1.13) | |
| 02–12 y | 1.92 (1.88; 1.96) | 1.11 (1.07; 1.15) | |
| 13–17 y | 1.57 (1.50; 1.63) | 1.08 (0.98; 1.18) | |
| All adults | 1.10 (1.09; 1.11) | 1.01 (1.00; 1.03) | |
| 18–40 y | 1.32 (1.25; 1.39) | 0.96 (0.87; 1.04) | |
| 41–64 y | 1.17 (1.10; 1.24) | 1.03 (0.95; 1.11) | |
| ≥65 y | 1.08 (1.01; 1.15) | 1.03 (0.94; 1.12) | |
|
| All participants | 1.09 (1.08; 1.10) | 0.92 (0.91; 0.93) |
| <18 y | 1.43 (1.42; 1.45) | 1.02 (1.01; 1.04) | |
| 02–12 y | 1.46 (1.44; 1.48) | 0.99 (0.97; 1.01) | |
| 13–17 y | 1.19 (1.17; 1.21) | 0.92 (0.90; 0.94) | |
| All adults | 1.00 (0.99; 1.02) | 0.91 (0.90; 0.95) | |
| 18–40 y | 1.07 (1.06; 1.09) | 0.87 (0.86; 0.89) | |
| 41–64 y | 1.00 (0.99; 1.04) | 0.86 (0.85; 0.88) | |
| ≥65 y | 0.88 (0.87; 0.90) | 0.97 (0.95; 0.98) | |
Results of the linear mixed-effects modeling.
Precision and accuracy of the CKD-EPI and Schwartz equations according to age and mGFR in children and adolescents.
| mGFR Category and Performance Index | All Participants <18 y | Children (2–12 y) | Adolescents (13–17 y) | |||
|---|---|---|---|---|---|---|
| CKD-EPI | Schwartz | CKD-EPI | Schwartz | CKD-EPI | Schwartz | |
|
| ||||||
| IQR (95% CI) | 0.33 (0.31; 0.34) | 0.23 (0.21; 0.24) | 0.39 (0.37; 0.42) | 0.22 (0.20; 0.23) | 0.35 (0.31; 0.41) | 0.21 (0.22; 0.27) |
| P10 (95% CI) | 8.4 (6.0; 10.0) | 46.7 (44.0; 49.6) | 2.8 (1.6; 4.0) | 49.1 (45.5; 52.6) | 18.1 (14.3; 21.8) | 42.7 (38.1; 47.6) |
| P30 (95% CI) | 29.4 (26.8; 32.0) | 88.6 (86.7; 90.4) | 16.8 (14.1; 19.0) | 89.3 (87.1; 91.5) | 51.4 (46.7; 56.1) | 87.2 (84.0; 90.3) |
|
| ||||||
| IQR (95% CI) | 1.04 (0.90; 1.14) | 0.31 (0.29; 0.45) | 0.79 (0.65; 0.99) | 0.26 (0.22; 0.37) | 0.67 (0.46; 0.93) | 0.37 (0.24; 0.61) |
| P10 (95% CI) | 0.8 (0.0; 2.5) | 33.6 (25.1; 42.1) | 0.0 (0.0; 0.0) | 31.1 (19.1; 42.0) | 1.6 (0.0; 5.0) | 36.1 (24.0; 48.1) |
| P30 (95% CI) | 10.9 (5.3; 16.5) | 67.5 (58.7; 75.6) | 0.0 (0.0; 0.0) | 62.1 (49.5; 74.6) | 21.3 (11.0; 35.5) | 72.1 (61.0; 83.9) |
|
| ||||||
| IQR (95% CI) | 0.42 (0.36; 0.46) | 0.23 (0.20; 0.26) | 0.35 (0.30; 0.40) | 0.21 (0.18; 0.24) | 0.41 (0.30; 0.51) | 0.21 (0.17; 0.32) |
| P10 (95% CI) | 3.0 (1.0; 5.1) | 49.5 (45.5; 52.5) | 0.0 (0.0; 0.0) | 46.4 (38.8; 54.4) | 7.1 (4.0; 10.2) | 45.1 (36.6; 54.3) |
| P30 (95% CI) | 10.3 (6.8; 13.9) | 89.0 (85.5; 92.7) | 0.0 (0.0; 0.0) | 90.4 (85.3; 94.8) | 23.9 (18.7; 29.1) | 87.6 (81.5; 93.7) |
|
| ||||||
| IQR (95% CI) | 0.32 (0.31; 0.34) | 0.21 (0.19; 0.23) | 0.28 (0.26; 0.31) | 0.18 (0.17; 0.21) | 0.24 (0.21; 0.27) | 0.20 (0.17; 0.24) |
| P10 (95% CI) | 11.2 (9.0; 13.5) | 49.5 (45.5; 52.5) | 3.8 (2.2; 5.5) | 51.7 (47.5; 56.0) | 27.0 (21.5; 32.4) | 43.4 (37.3; 49.4) |
| P30 (95% CI) | 38.5 (35.5; 41.8) | 91.2 (89.6; 93.5) | 23.3 (19.7; 26.8) | 92.0 (89.8; 94.3) | 70.7 (65.1; 72.3) | 90.6 (87.0; 94.2) |
IQR: IQR of the ratio of eGFR to mGFR; P10 and P30: within 10% and 30% limits above and below the mGFR.
Precision and accuracy of the CKD-EPI and Schwartz equations according to age and mGFR in adults (≥18 y).
| mGFR Category and Performance Index | All Adults | 18–40 y | 41–64 y | ≥65 y | ||||
|---|---|---|---|---|---|---|---|---|
| CKD-EPI | Schwartz | CKD-EPI | Schwartz | CKD-EPI | Schwartz | CKD-EPI | Schwartz | |
|
| ||||||||
| IQR (95% CI) | 0.30 (0.29; 0.31) | 0.33 (0.33; 0.35) | 0.27 (0.26; 0.28) | 0.26 (0.25; 0.27) | 0.30 (0.29; 0.31) | 0.34 (0.32; 0.35) | 0.33 (0.31; 0.34) | 0.40 (0.38; 0.41) |
| P10 (95% CI) | 38.1 (37.1; 39.0) | 33.0 (32.3; 34.2) | 38.3 (36.3; 40.2) | 33.5 (31.7; 35.6) | 38.5 (37.1; 39.8) | 34.1 (32.8; 35.5) | 36.7 (34.5; 38.9) | 30.3 (28.2; 33.4) |
| P30 (95% CI) | 79.8 (79.0; 80.6) | 77.9 (77.6; 79.3) | 81.0 (79.5; 82.6) | 86.5 (85.0; 87.8) | 80.0 (79.0; 81.1) | 78.7 (77.6; 79.8) | 77.6 (75.7; 79.5) | 67.5 (65.4; 69.7) |
|
| ||||||||
| IQR (95% CI) | 0.39 (0.38; 0.40) | 0.40 (0.38; 0.41) | 0.40 (0.36; 0.44) | 0.32 (0.28; 0.33) | 0.39 (0.38; 0.42) | 0.39 (0.36; 0.41) | 0.41 (0.40; 0.48) | 0.41 (0.40; 0.48) |
| P10 (95% CI) | 30.3 (28.8; 31.7) | 29.4 (28.0; 31.0) | 25.4 (21.7; 29.1) | 35.0 (31.0; 39.1) | 30.0 (26.1; 34.0) | 29.8 (27.7; 31.8) | 32.4 (30.0; 35.0) | 26.4 (24.0; 28.8) |
| P30 (95% CI) | 69.1 (67.8; 70.6) | 67.1 (65.7; 68.7) | 63.8 (59.7; 68.0) | 81.4 (78.1; 84.7) | 68.5 (64.5; 72.5) | 68.7 (66.7; 70.7) | 72.4 (70.0; 74.8) | 58.7 (56.3; 61.4) |
|
| ||||||||
| IQR (95% CI) | 0.29 (0.28; 0.30) | 0.26 (0.25; 0.27) | 0.29 (0.27; 0.31) | 0.22 (0.21; 0.24) | 0.28 (0.27; 0.30) | 0.28 (0.26; 0.29) | 0.23 (0.22; 0.25) | 0.27 (0.25; 0.28) |
| P10 (95% CI) | 37.7 (36.3; 39.3) | 38.8 (37.1; 40.5) | 32.1 (28.7; 35.5) | 37.7 (34.1; 41.1) | 37.8 (35.7; 40.0) | 39.2 (37.1; 41.4) | 45.5 (41.1; 49.8) | 40.0 (34.7; 43.1) |
| P30 (95% CI) | 81.5 (80.1; 82.8) | 86.3 (85.1; 87.5) | 74.8 (71.6; 80.0) | 89.7 (87.5; 92.0) | 82.0 (80.3; 83.7) | 85.0 (83.4; 86.7) | 89.0 (86.3; 91.7) | 86.4 (83.4; 89.4) |
|
| ||||||||
| IQR (95% CI) | 0.20 (0.20; 0.22) | 0.22 (0.21; 0.24) | 0.32 (0.28; 0.33) | 0.40 (0.36; 0.44) | 0.19 (0.18; 0.20) | 0.24 (0.23; 0.26) | 0.13 (0.11; 0.18) | 0.27 (0.22; 0.31) |
| P10 (95% CI) | 51.4 (49.3; 53.4) | 32.3 (30.1; 34.6) | 48.8 (45.7; 51.7) | 30.1 (27.4; 32.8) | 53.8 (51.7; 56.0) | 33.4 (31.3; 35.4) | 50.0 (38.5; 61.5) | 37.5 (26.3; 48.6) |
| P30 (95% CI) | 95.1 (94.2; 96.0) | 86.3 (84.8; 87.7) | 93.6 (92.1; 95.1) | 86.6 (84.6; 88.7) | 96.6 (95.8; 97.4) | 85.6 (84.1; 87.2) | 90.3 (83.4; 97.1) | 90.3 (83.4; 97.1) |
IQR: IQR of the ratio of eGFR to mGFR; P10 and P30: within 10% and 30% limits above and below the mGFR.
Fig 2Estimation of P30 accuracy of the CKD-EPI and Schwartz equations according to age class and mGFR.
Fig 3Box plots showing eGFR/mGFR ratios according to age class and stage of chronic kidney disease.